Genomics

Gene editing in 2025-2026 has entered a phase transition from proof-of-concept to clinical reality. The first CRISPR therapy (Casgevy) was approved in late 2023, and by late 2025 there are 19 base and prime editing clinical trials underway across 5 countries. The most dramatic clinical result is a single CRISPR infusion that cut LDL cholesterol by 50% in a first-in-human trial at Cleveland Clinic — a potential replacement for lifelong statin medication. Meanwhile, the editing tools themselves continue to advance: prime editing now offers disease-agnostic treatment of nonsense mutations via suppressor tRNAs, and epigenetic editing has demonstrated gene reactivation without any DNA cuts.

The field's trajectory is being reshaped by two forces. First, delivery science is catching up to editing capability — lipid nanoparticles have proven they can deliver CRISPR to liver cells in humans, opening the door to one-time treatments for cardiovascular disease. Second, AI is compressing development timelines: CRISPR-GPT (Stanford, 2025) enabled a novice researcher to achieve first-attempt gene editing success, and similar AI copilots will likely accelerate the entire therapeutic pipeline from target identification through clinical trial design.

Frontier — What's Moving Now

• Disease-agnostic prime editing — Suppressor tRNAs address ~30% of rare diseases. Error rates improved to 1-in-101.
• Epigenetic editing without DNA cuts — Safer approach reactivates silenced genes via demethylation. Applied to Sickle Cell (fetal hemoglobin). Cell studies only.
• One-time cardiovascular treatment — CRISPR infusion cuts LDL -50%, triglycerides -55% in 15 patients. Sustained 60+ days.
• AI-accelerated gene therapy — CRISPR-GPT compresses development timelines. Novice first-attempt success.
• 19 clinical trials expanding — Base and prime editing trials in 5 countries, beyond first-gen CRISPR-Cas9.

Concept Map

Concepts

Entities

Timeline

See timeline.md for chronological developments (2016 through January 2026).

Research Frontier

See frontier.md for active research directions, breakthroughs, and knowledge gaps.

Sources